For years, SNY has been telling investors that an approved generic Lovenox was an impossibility based on the science. They presumably said similar things to bankers, distributors, suppliers, prospective employees, etc. If the FDA approval of generic Lovenox stands, SNY’s executives thus come across as ignorant, disingenuous, or both.
Please note: I’m not saying the above is a reason for the Court to give SNY’s argument any weight whatsoever at the hearing on Aug 17.
Market Data 
Markets 
AI
